Pasireotide Acetate is a stable cyclohexapeptide somatostatin mimic

BIM 23056 Acetate is a  potent and surmountable human recombinant sst5 receptor antagonist.

BIM-23190 aceate, a somatostatin analog, a selective agonist of SSTR2 and SSTR5. BIM-23190 can be used in cancer and acromegaly studies.

Cortistatin-14 acetate, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 acetate shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties

Potent somatostatin receptor 1 (sst1) agonist; displays selectivity for sst1 (IC50 values are 30.9 nM, 345 nM, > 1 μM, > 10 μM and > 10μM for human sst1, sst3, sst4, sst2 and sst5 respectively). Attenuates somatostatin release in the rat nucleus accumbens

Peptide agonist for sst2 and sst5 somatostatin receptors. IC50/Kd values (nM) at cloned human somatostatin receptors are: > 1000 (sst1), 0.2 - 1.5 (sst2), 27 - 36 (sst3), > 127 (sst4), and 0.06 - 23 (sst5).

Angiopeptin is a synthetic octapeptide analog of somatostatin; suppresses accelerated transplant atherosclerosis in rabbit heart arteries.

PRL 3195 is a somatostatin receptor antagonist, exhibiting K i values of 6, 17, 66, 1000, and 1000 nM for human somatostatin receptors sst 5 , sst 2 , sst 3 , sst 1 , and sst 4, respectively [1].

Cortistatin-14 (TFA), a neuropeptide resembling somatostatin-14 in structure, operates through interaction with somatostatin receptors (sst1-sst5). This compound exhibits anticonvulsive and neuroprotective effects alongside significant anti-inflammatory properties [1] [2] [3] [4].

Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, acts as a partial agonist at sst 2/sst 5 receptors, exhibiting IC50 values of 0.26 nM and 6.92 nM, respectively. This compound effectively inhibits the release of growth hormone and the production of insulin-like growth factor-1 (IGF-1). Additionally, it either inhibits adenylate cyclase activity or promotes extracellular acidification. Notably, Angiopeptin TFA shows promise for use in coronary atherosclerosis research [1] [2].

CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. For the recombinant sst2, sst1, sst3, sst4 and sst5 receptors, the pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48, respectively.

CYN 154806 is a potent and selective somatostatin sst2 receptor antagonist, The pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.